As of 2026-03-21, the EV/EBITDA ratio of Guardant Health Inc (GH) is -30.51. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. GH's latest enterprise value is 12,298.86 mil USD. GH's TTM EBITDA according to its financial statements is -403.10 mil USD. Dividing these 2 quantities gives us the above GH EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 11.6x | 9.4x |
| Forward P/E multiples | 6.9x - 14.3x | 9.0x |
| Fair Price | (31.75) - (44.35) | (37.01) |
| Upside | -137.3% - -152.1% | -143.4% |
| Date | EV/EBITDA |
| 2026-03-18 | -31.19 |
| 2026-03-17 | -31.67 |
| 2026-03-16 | -31.16 |
| 2026-03-13 | -30.61 |
| 2026-03-12 | -30.13 |
| 2026-03-11 | -31.44 |
| 2026-03-10 | -32.24 |
| 2026-03-09 | -32.47 |
| 2026-03-06 | -32.47 |
| 2026-03-05 | -32.92 |
| 2026-03-04 | -33.06 |
| 2026-03-03 | -33.15 |
| 2026-03-02 | -32.80 |
| 2026-02-27 | -33.35 |
| 2026-02-26 | -34.67 |
| 2026-02-25 | -33.79 |
| 2026-02-24 | -33.84 |
| 2026-02-23 | -33.52 |
| 2026-02-20 | -36.34 |
| 2026-02-19 | -37.41 |
| 2026-02-18 | -37.75 |
| 2026-02-17 | -37.65 |
| 2026-02-13 | -36.91 |
| 2026-02-12 | -36.23 |
| 2026-02-11 | -37.80 |
| 2026-02-10 | -36.97 |
| 2026-02-09 | -37.07 |
| 2026-02-06 | -35.93 |
| 2026-02-05 | -34.80 |
| 2026-02-04 | -37.33 |
| 2026-02-03 | -39.58 |
| 2026-02-02 | -40.18 |
| 2026-01-30 | -39.90 |
| 2026-01-29 | -38.74 |
| 2026-01-28 | -38.50 |
| 2026-01-27 | -40.08 |
| 2026-01-26 | -40.13 |
| 2026-01-23 | -40.13 |
| 2026-01-22 | -40.96 |
| 2026-01-21 | -40.46 |
| 2026-01-20 | -40.17 |
| 2026-01-16 | -39.28 |
| 2026-01-15 | -39.23 |
| 2026-01-14 | -38.13 |
| 2026-01-13 | -37.58 |
| 2026-01-12 | -37.80 |
| 2026-01-09 | -38.64 |
| 2026-01-08 | -38.18 |
| 2026-01-07 | -38.56 |
| 2026-01-06 | -39.35 |